Delving into the Latest Updates on HTMC0769 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

HTMC0769

Target-

Action-

Mechanism-

Therapeutic Areas

Respiratory Diseases

Active Indication

Respiratory Distress Syndrome, Acute

Inactive Indication-

Originator Organization

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Active Organization

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价注射用HTMC0769在中国健康成年受试者中单次给药剂量递增（SAD）研究和多次给药剂量递增（MAD）研究给药后的安全性及耐受性。次要目的：评价注射用HTMC0769在中国健康成年受试者中SAD研究和MAD研究给药后的药代动力学（Pharmacokinetics，PK）特征。探索目的：探索注射用HTMC0769对健康受试者QT/QTc间期的影响。

[Translation]

Primary objective: To evaluate the safety and tolerability of HTMC0769 for injection in a single ascending dose (SAD) study and a multiple ascending dose (MAD) study in healthy Chinese adult subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of HTMC0769 for injection in a SAD study and a MAD study in healthy Chinese adult subjects. Exploratory objective: To explore the effect of HTMC0769 for injection on the QT/QTc interval in healthy subjects.

Start Date31 Mar 2025

Sponsor / Collaborator

Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.

100 Clinical Results associated with HTMC0769

Login to view more data

100 Translational Medicine associated with HTMC0769

Login to view more data

100 Patents (Medical) associated with HTMC0769

Login to view more data

100 Deals associated with HTMC0769

Login to view more data